Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache

This study has been completed.
Information provided by:
Kern Medical Center Identifier:
First received: February 6, 2006
Last updated: January 23, 2008
Last verified: January 2008
Migraine headaches have previously been shown to be responsive to intranasal lidocaine in a small study. Using a nebulizer to administer the drug would improve the feasibility of using the treatment. It would also spare the patient narcotics with their attendant side effects. Because of the potential for placebo effect a placebo control is necessary in this study.

Condition Intervention
Migraine Headache
Drug: Lidocaine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache

Resource links provided by NLM:

Further study details as provided by Kern Medical Center:

Primary Outcome Measures:
  • Resolution of symptoms

Secondary Outcome Measures:
  • Improvement in 10 point pain score

Estimated Enrollment: 150
Study Start Date: January 2002
Estimated Study Completion Date: April 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets IHS criteria for migraine

Exclusion Criteria:

  • Pregnant
  • Breast feeding
  • Allergic to Lidocaine
  • Worst or first Headache
  • Abnormal neurological exam
  • Substance abuse within 6 months
  • Cardiac, liver or pulmonary disease
  • Participation n another study within 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00287781

United States, California
Kern Medical Center
Bakersfield, California, United States, 93305
Sponsors and Collaborators
Kern Medical Center
Principal Investigator: Rick McPheeters, DO FAAEM Kern Medical Center UCLA
  More Information Identifier: NCT00287781     History of Changes
Other Study ID Numbers: #04028
Study First Received: February 6, 2006
Last Updated: January 23, 2008

Keywords provided by Kern Medical Center:

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 23, 2017